B. Margono

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

T. Mok, Yi-long Wu, S. Thongprasert, 2009, The New England journal of medicine.

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

T. Mok, Yi-long Wu, S. Thongprasert, 2017, Lung cancer.

Comparative Study of Patients in Correct Usage of and Preference for the Swinghaler and Turbuhaler Multidose Inhalers

K. Ruxrungtham, C. Bai, B. Margono, 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

T. Mok, Yi-long Wu, S. Thongprasert, 2015, Clinical Cancer Research.

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Li Zhang, Hongming Pan, Chong-Jen Yu, 2013, The Lancet. Oncology.

A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.

T. Mok, Yi-long Wu, S. Thongprasert, 2012 .

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

S. Thongprasert, P. Sunpaweravong, B. Margono, 2009, The New England journal of medicine.